Full Press Release Details
cemdisiran dosed subcutaneously every 12 weeks demonstrates rapid deep and sustained disease control in generalized myasthenia gravis gmg phase 3 trial.
REGN
cemdisiran dosed subcutaneously every 12 weeks demonstrates rapid deep and sustained disease control in generalized myasthenia gravis gmg phase 3 trial
Key Takeaway: cemdisiran dosed subcutaneously every 12 weeks demonstrates rapid deep and sustained disease control in generalized myasthenia gravis gmg phase 3 trial